

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.\***

*(a joint stock limited company established in the People’s Republic of China with limited liability)*

**(Stock Code: 8058)**

**FURTHER ANNOUNCEMENT ON THE PROPOSED TRANSFER OF LISTING FROM THE GROWTH ENTERPRISE MARKET TO THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

Reference is made to the announcement of Shandong Luoxin Pharmaceutical Group Stock Co., Limited (the “**Company**”) dated 21 December 2015 (the “**Announcement**”) in relation to the submission of a formal application to the Stock Exchange for the proposed Transfer of Listing (the “**Application**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The latest Application was submitted to the Stock Exchange on 21 December 2015. As six months had passed since the submission of the latest Application, the Application automatically lapsed on 20 June 2016.

The Company is still processing the Application and the Board believes that the lapse of the Application has no material adverse effect to the business operation and/or finance of the Company.

The Company plans to re-submit a new application for the proposed Transfer of Listing and a separate announcement will be made as and when appropriate.

By order of the Board  
**Shandong Luoxin Pharmaceutical Group Stock Co., Ltd**  
**Liu Baoqi**  
*Chairman*

PRC, 12 August 2016

\* *For identification purpose only*

*As at the date of this announcement, the Board comprises 10 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors, Mr. Liu Zhenhai (劉振海) is a non-executive Director; Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Du Guanhua (杜冠華) and Ms. Huang Huiwen (黃慧文) are independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from its date of publication and on the Company’s designated website at: <http://shandongluoxin.quamir.com>.*